Jun 14, 2021 / 09:30PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Okay. Welcome to the afternoon sessions of the Second Annual Virtual Napa conference. Next here will be the real thing. Fingers crossed. My name is Geoff Meacham, I'm the senior biopharma analyst here, and I have Alex Hammond from my team with me as well. And we're thrilled to have Alector with us for this last session and speaking on behalf of Alector is President and COO, Shehnaaz Suliman. How are you doing, Shehnaaz? It's good to see you.
Shehnaaz Suliman - Alector, Inc. - President, COO & Interim Chief Business Officer
Doing great. Thanks for having us.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research AnalystYes. So we'll start it off with maybe just sort of a recap of the events of early last week with Biogen's aducanumab obviously, doesn't directly affect you, but I wanted to kind of get your thoughts of the FDA decision and maybe what that means for Alzheimer's or
Trustpilot
